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Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; 
however, new therapies targeting specific tumor-related molecular characteristics may 
help certain patient cohorts. Emerging preclinical data have shown that inhibition of 
mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes 
leads to inhibition of tumorigenesis in vitro and in vivo. Early phase II studies of mono-
mTOR inhibition have not shown promise. However, studies have shown that combined 
inhibition of multiple steps along the mTOR signaling pathway may lead to sustained 
responses by targeting mechanisms of tumor resistance. Coordinated inhibition of 
mTOR along with specific KRAS-dependent mutations in molecularly defined PDAC 
subpopulations may offer a viable alternative for treatment in the future.
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inTRODUCTiOn
epidemiology
Pancreatic ductal adenocarcinoma (PDAC) remains the fourth leading cause of cancer-related 
mortality throughout the United States, with 12.3 new cases reported per 100,000 men and women 
annually and 10.9 deaths reported per 100,000 men and women annually (1). The lifetime risk 
of developing pancreatic cancer is approximately 1.5% among men and women, with about 6.7% 
survival rate 5 years from diagnosis (1).
Pancreatic ductal adenocarcinoma is associated with poor prognosis. This is related to lack of 
standardized preventive screening, advanced age during diagnosis with median age being 71 years 
old, and advanced stage during diagnosis which has allowed only 15–20% to be surgically resectable 
at the time of presentation (2). These factors, and the aggressive nature of PDAC, has significantly 
limited the success of current treatment options, yielding continued low survival rates even in cases 
which are amenable to surgical resection, modest responses to chemotherapy and radiation, as well 
as development of resistance to such therapies (2, 3).
Standards of Treatment
Resectability of PDAC is determined clinically by the patients underlying comorbidities and ability 
to tolerate major surgery, and radiographically based on involvement of the surrounding major vas-
culature including the superior mesenteric vein and artery, portal vein, celiac artery, and its branches, 
including the hepatic artery (2, 4). For resectable disease (stage I or II), pancreaticoduodenectomy is 
performed for tumors involving the head and uncinate of the pancreas, whereas distal pancreatectomy 
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is performed for tumors of the body and tail and are considered 
potentially curative (2). However, only 15–20% of the patients are 
considered surgical candidates with many of them found to have 
microscopically positive margins (R1) discovered after surgery 
on final pathological review (2, 5), and others are considered 
medically unfit often secondary to malnutrition or advanced age 
and would not benefit from surgical resection or may experience 
major complications after pancreatic resection (6, 7).
Adjuvant (postoperative) therapy with the intention of reduc-
ing locoregional and metastatic recurrence has been shown to 
improve survival compared to postoperative observation alone 
(6). The Charité Onkologie (CONKO)-001 trial and the European 
Study Group for Pancreatic Cancer (ESPAC)-3 trial have investi-
gated and established gemcitabine or 5-fluorouracil (FU) as effec-
tive avenues for adjuvant chemotherapy compared to observation 
(6). Neoadjuvant and adjuvant combination chemotherapy 
including fluorouracil, irinotecan, oxaliplatin, and leucovorin 
(FOLFIRINOX) and gemcitabine plus albumin-bound paclitaxel 
particles (nab-paclitaxel) is still being investigated, and adjuvant 
radiation has demonstrated mixed results (3, 6).
Stage III disease is divided into borderline resectable disease 
[<180° contact with the superior mesenteric artery (SMA) and 
locally advanced, unresectable disease (>180° contact with 
SMA)] (6). Neoadjuvant (preoperative) therapy is often recom-
mended for borderline resectable disease to address the high 
probability of positive margins at resection (6). The combina-
tion of FOLFIRINOX and gemcitabine + nab-paclitaxel for the 
treatment of Stage III locally advanced unresectable tumors has 
limited data, but is commonly used. Again, adjuvant radiation is 
not adequately supported (2).
Curative resection is not recommended in stage IV PDAC, 
and treatment focuses on palliation. The use of FOLFIRINOX or 
gemcitabine + nab-paclitaxel has been shown to extend survival 
by at least 2 years in at least 10% of the patients, survival numbers 
that were rarely seen before and now represent standard first-line 
options, particularly in patients with good performance status 
[ECOG 0–1 (2, 8)]. Overall, multidisciplinary, symptomatic, and 
supportive therapies play an integral role in management (6).
Rationale for mTOR Pathway
The investigation of genetic and molecular characteristics of 
PDAC remains a focus of current innovations in an effort to 
identify potential therapeutic targets. Genomic analysis of PDAC 
has revealed complex mutational patterns including near ubiqu-
itious activation of KRAS, inactivation of >50% of major genetic 
pathways, such as TP53, SMAD4, and CDKN2A, involvement of 
10% of genes in chromatin modification and DNA damage repair, 
and a collection of infrequently mutated genes that contribute 
to heterogeneity and create challenges in the development of 
targeted therapies (9). Affected gene mutations known to be 
important in pancreatic cancer turmorigenesis include TP52, 
SMAD4, CDKN2A, ARID1A, and ROBO2. In one evaluation, 
utilizing whole genome sequencing and copy number variation 
of PDAC, combining structural variation events with deleterious 
point mutations increased the prevalence of inactivation events 
to 74% for TP53, 31% for SMAD4, and 35% for CDKN2A (9).
The KRAS proto-oncogene is mutated in 90% of PDAC, with 
somatic alterations and locally rearranged, focal amplifications 
being quite common (6, 9, 10). Single point mutations in codon 
12, 13, 59, or 61 of exon 2 and exon 3 of the KRAS oncogene impair 
intrinsic GTPase activity of KRAS and lead to a permanent active 
KRAS signaling pathway, resulting in proliferation and survival 
of cells (11). Mutation in KRAS leads to the uncontrolled activa-
tion of downstream intracellular signaling pathways such as the 
RAF/MEK/extracellular signal regulated kinase (ERK) and AKT 
contributing to tumor cell proliferation and survival (6, 12).
While wild-type KRAS has been described as a predictive 
marker for treatment success of EGFR, inhibitors such as erlotinib 
or cetuximab and panitumumab in metastatic non-small cell 
lung and colorectal cancer, its predictive and prognostic value in 
PDAC has not been clearly established (13). Inhibitors of KRAS 
have been largely unsuccessful in clinical trials and emphasis has 
been placed on its downstream pathways (6).
Additional downstream players of KRAS include phosphati-
dylinositol 3-kinase (PI3K) and AKT, which link ligation of 
growth factor receptors to the phosphorylation and activation 
of the serine/threonine kinase, mammalian target of rapamy-
cin (mTOR), further downstream (14, 15). This downstream 
effector plays a role in cell survival, growth, proliferation, and 
motility, as well as a regulation of apoptosis (14, 15). mTOR 
exists as two complexes: mTORC1 that is rapamycin sensitive 
and mTORC2 that is largely rapamycin insensitive. mTORC1 
interacts with the accessory protein Raptor-to-phosphorylate 
effectors S6 kinase 1, which ultimately enhances the translation 
of mRNAs, including ribosomal proteins, elongation factors, 
and insulin growth factor 2 (14). mTORC1 also phosphoryl-
ates 4EBP1 promoting dissociation of eIF4E from 4EBP1, thus 
relieving the inhibitory effect of 4EBP1 on eIF4E-dependent 
translation initiation, which again ultimately leads to increased 
translation of mRNAs (14). mTORC2 interacts with its 
companion RICTOR to phosphorylate PKC alpha and AKT 
contributing to cell survival, migration, and regulation of the 
actin cytoskeleton (14).
The mTOR complex is also closely related to the insulin/IGF-1 
pathway. Decrease of adenosine triphosphate (ATP) production 
by metformin, for example, leads to AMPK activation and dis-
ruption of insulin/IGF-1 signaling through inhibition of mam-
malian target of rapamycin (8, 16). Inhibition of mTOR signaling, 
in turn, results in decreased protein synthesis and cell growth. 
Metformin can also inhibit mTOR signaling through activation 
of AMPK-independent pathways, including Rag GTPase (17) 
and REDD1 (18). AMPK-induced activation of tumor suppres-
sor 53 (p53) and subsequent cell cycle arrest represents another 
potential mechanism of action of metformin in pancreatic cancer 
models (19). Clearly, the mTOR pathway is a key player in many 
biological processes including cell growth, regulation of actin 
cytoskeleton, gene transcription, ribosome biogenesis, mRNA 
translation, and cell survival and proliferation (14).
Upstream of mTOR, the PI3K/AKT pathway is influenced by 
PTEN, the negative regulator of PI3K signaling, which decreases 
its expression in many cancers including pancreatic, and may be 
downregulated through several mechanisms including mutation, 
deletion, and methylation (15).
TABLe 1 | The preclinical development of mTOR inhibitors in pancreatic 
cancer.
Study agent Source in which antitumor 
activity was demonstrated
Reference
Rapamycin BxPC3, Su86.86, HS700T, HPAF, 
and Capan-1 cells (in vitro)
(21)
Rapamycin PANC-1 cells (in vitro) (24)
INK-128 Primary human PDAC, PANC-1, 
and MIA PaCa-2 cells (in vitro)
(25)
BEZ235 ± PD0325901, 
PKI-587 ± PD0325901, and 
GDC-0980 ± PD0325901
MIA PaCa-2 and PANC-1 cells 
(in vitro)
(26)
Rapamycin ± gemcitabine Kras PTEN-deficient mice 
model (Pdx1-Cre, KrasG12D/+, 
Ptenflox/+, in vivo)
(27)
AZD8055 ± erlotinib PANC-1 and Capan-1 cells 
(in vitro); mouse PANC-1 
xenografts (in vivo)
(3)
Rapamycin ± XRT (4 Gy) PC-2 and PANC-1 cells (in vitro) (28)
INK128 ± XRT PSN1, MIA PaCa-2, and PANC-1 
cells (in vitro), mouse PSN1 
xenografts (in vivo)
(29)
Rapamycin ± metformin Mouse Panc02 xenografts (in vivo) (30)
AZD8055 + BEZ235 Kras p53-inactivated mice model 
(Pdx1-Cre, LSL-KRASG12D, 
p53Lox/+, in vivo)
(31)
INK-128, mTORC1/2 inhibitor; PD0325901, MEK inhibitor; BEZ235, dual PI3K/mTOR 
kinase inhibitor; PKI-587, dual PI3K/mTOR kinase inhibitor; GDC-0980, dual PI3K/
mTOR kinase inhibitor; AZD8055, mTORC1/2 inhibitor; XRT, radiation therapy; Gy, gray.
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Clinically investigated mTOR inhibitors include rapamycin 
(sirolimus) and its analogs, such as temsirolimus, everolimus, 
and ridaforolimus. These analogs combine with mTOR acces-
sory protein FKBP12 forming complexes that bind to mTOR 
and inhibit mTORC1 downstream signaling, preventing S6K1 
and 4EBP1 phosphorylation (14). While FKBP12-rapamycin 
complex cannot bind directly to mTORC2, prolonged treatments 
can disturb mTORC2 assembly and inhibit the phosphorylation 
of its downstream substrate AKT (14). However, inhibition of 
mTORC1 without mTORC2 inhibition may stimulate tyrosine 
kinase activity leading to AKT upregulation, a feedback loop that 
has been thought to contribute to mTOR resistance. Compared 
to rapamycin and its analogs, agents that were able to inhibit 
mTORC1 and mTORC2 were more effective in preclinical evalu-
ations (20). These inhibitors have already been demonstrated to 
be promising therapeutic agents in other types of malignancies. 
A high response rate was observed with everolimus in Phase II 
trials in Hodgkin lymphoma, non-Hodgkin’s lymphoma, and 
breast cancer, and temsirolimus in Phase II/III trials in endome-
trial cancer and mantle-cell lymphoma (14).
PReCLiniCAL STUDieS
In Vitro mTOR inhibitor Studies
In vitro studies have demonstrated diverse effects of mTOR 
inhibition on cell cycle arrest, autophagy, decreased desmo-
plastic inflammation, and inhibited epithelial-to-mesenchymal 
transition in preclinical studies of pancreatic cancer (Table  1). 
Rapamycin-induced autophagy and apoptosis in BxPC3, Su86.86, 
HPAF, Capan-1, and HS700T PDAC cell lines that correlated 
to cell line-specific levels of mTOR activity (21). Novel agents 
Alisertib and Plumbagin, induced cell cycle arrest, promoted 
autophagy, and inhibited epithelial-to-mesenchymal transition in 
PANC-1 and BxPC3 cell lines through inhibition of PI3K/AKT/
mTOR signaling (22, 23).
Mammalian target of rapamycin inhibition with first and 
second generation inhibitors also leads to class specific mecha-
nisms of resistance. As demonstrated across several cancer cell 
lines, resistance to mTOR-related cytotoxicity has been limited 
by feedback activation via the IGF-1R–AKT signaling pathway 
imparting drug resistance (32). In PANC-1 and MiaPaCa-2 cells, 
rapamycin treatment leads to resistance mediated by AKT phos-
phorylation despite inhibitory effects on proliferation of PANC-1 
cells (24). Furthermore, treatment with second generation mTOR 
inhibitors, such as KU63794 and PP242, leads to treatment resist-
ance via increased ERK activation (26).
Novel mTOR inhibitors may overcome resistance mecha-
nisms by dual inhibition of mTOR complexes. Primary and 
transformed pancreatic cancer cells exhibit a concentration- and 
time-dependent arrest of growth upon dual mTOR inhibition 
with INK-128 via 4E-BP1, S6K1, and AKT (25). Furthermore, 
INK-128 also sensitizes cells to treatment with gemcitabine. Use 
of U126 or PD0325901 MEK inhibitors prevents ERK overac-
tivation induced by NPV-BEZ235 (dual PI3K/mTOR kinase 
inhibitor) leading to synergistic inhibition of proliferation in a 
dose-dependent manner in PANC-1 and MiaPaCa-2 cells (26).
In Vivo mTOR inhibition Studies
Animal models have demonstrated that agents targeting the 
mTOR pathway can lead to significant inhibition of prolif-
eration, differentiation, and tumor progression in specific 
PDAC subpopulations (Table 1). Enhanced inhibition of tumor 
differentiation and progression by rapamycin was demonstrated 
to be specifically dependent on loss of PTEN in KRAS-mutant 
mice (KC) (27). Inhibition of mTOR improved survival and 
induced tumor shrinkage downstream of mTOR via S6 leading 
to regression of tumors into benign, relatively non-proliferative 
cysts. In contrast, KRAS-mutant mice tumors driven by mutant 
p53 (KPC) did not respond to rapamycin treatment, which has 
other distinct pathways that are mTOR independent (27, 33). In 
transgenic mouse models in which mTOR was hyperactivated 
either through the KRAS/MEK/ERK cascade, by loss of PTEN, 
or through TSC1 haploinsufficiency, single inhibition of mTOR 
or MEK elicited strong feedback activation of ERK or AKT (34). 
In this study, rapamycin and PD98059 individually lead to ERK 
and AKT feedback-mediated resistance; however, dual inhibition 
with LY294002 and PD98059 ameliorated oncogenic activity. 
Furthermore, PTEN-deficient cells responded to LY294002 
and/or rapamycin treatment, but not PD98059, consistent with 
aforementioned study by Morran and colleagues (27). Analysis of 
downstream targets in pancreatic cancer cell lines identified that 
MEK/ERK/TSC/mTOR signaling is dependent on ALDH1A3 
function and high expression of ALDH1A3 is associated with 
an aggressive subtype of PDAC (34). Therefore, in ALDH1A3-
positive PDAC, targeting of ALDH1A3 may be of benefit in 
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addition to inhibiting the MEK/ERK/mTOR cascade. Moreover, 
PTEN haploinsufficiency also appears to promote tumorigenesis 
through PI3K-dependent NF-κB activation in pancreatic cancer 
mouse models (35). Notably, treatment with LY294002 abrogated 
NF-κB activation in PTEN haploinsufficient pancreatic cancer 
models in vivo (35).
Use of second generation mTOR inhibitors offers similar 
distinct mechanisms of tumorigenesis inhibition. AZD8055, a 
second generation mTOR inhibitor, used with erlotinib (an EGRF 
inhibitor) leads to proliferative inhibition in PANC-1 xenografts 
(3). Use of both AZD8055 and erlotinib abolished EGFR/AKT 
feedback activation-related resistance associated with AZD8055 
monotherapy. The combination of AZD8055 and the dual 
PI3K-mTOR inhibitor BEZ235 delayed PDAC progression and 
prolonged survival in KRAS-mutant PDAC mice in vivo (31).
mTOR inhibitors as Radiosensitizers
First and second generation mTOR inhibitors both act to sen-
sitize PDAC to radiation therapy in  vitro (Table  1). PC-2 and 
PANC-1 cells treated with rapamycin exhibited a dose-dependent 
radiosensitizing effect on cell proliferation arrest leading to G2/M 
phase cell cycle arrest (28). PSN1 cells exhibited a dose-dependent 
inhibition of proliferation and tumor growth delay in athymic 
nude mice xenografts following single and fractionated doses of 
radiation with INK-128 pretreatment (29).
Metformin-Related mTOR inhibition  
of PDAC
Metformin exhibits diverse effects on PDAC carcinogenesis 
through both mTOR-dependent and -independent mechanisms 
(36). Metformin mTOR activation occurs via AMPK-mediated 
(16, 37), Rag GTPase-mediated (17), and REDD1-mediated 
mechanisms (18). Metformin may also ameliorate aberrant 
signaling and feedback inhibition via insulin-like growth factor-1 
receptor (IGF-1R)–AKT signaling by improving insulin tissue 
sensitivity (16). In MIAPaca2 and PANC1 cells explanted into 
an athymic nude mice xenograft, metformin inhibits pancreatic 
cell growth via mTOR1 inhibition, which was demonstrated to be 
dose dependent (38). Combined treatment with metformin and 
rapamycin of Panc02 cells transplanted into diet-induced obese 
(DIO) C57BL/6 mice lead to significantly reduced pancreatic 
tumor growth and mTOR-related signaling (30).
inhibition of mTOR in Human PDAC
In genetic profiles of human tumors, loss of or low PTEN 
expression and hyperphosphorylation of AKT has been found 
to be present in around 70% of the cases and PTEN genomic loss 
(deletion of one or two copies of the PTEN locus) in 15% of the 
cases (35). Even single-copy PTEN loss, in the setting of KRAS-
initiated pancreatic transformation, retains its tumorigenic 
potential by increasing epithelial proliferation, contributing to 
an aggressive histologic phenotype, and activating PI3K/AKT 
and ERK signaling in vivo (35). Biopsies of human pancreatic 
cancer cells obtained through endoscopic ultrasonography that 
overexpressed pS6 (a downsteam effector activated by mTOR 
overexpression) show sensitivity to  rapamycin inhibition ex 
vivo (21). Recent data examining resected PDAC biology 
utilizing “Multi-Omic” analysis suggest that alterations in 
mTOR pathway are very common and potentially important 
for treatment (39–42). Out of 117 PDAC samples included in 
one analysis, 43% of the patients had a therapeutic response 
related to a molecular abnormality or mechanism/pathway 
identified through next-generation sequencing (NGS) (41). 
Actionable findings linked to a specific treatment options 
identified by NGS included mutations in BRCA2 (5%), PALB2 
(1%), ATM (4%), BRAF (2%), PIK3C/PIK3R (7%), STK11 
(5%), amplification of ERBB2 (3%), FGFR (2%), PDGFR (2%), 
and RET fusions (2%) (42). Further analysis with incorpora-
tion of immunohistochemistry (IHC) in this cohort refined 
and expanded chemotherapy treatment options in all patients 
(41). A subset of PDAC with integration of phosphoproteomics 
(PHO) in their NGS and IHC analysis revealed pathway activa-
tion (e.g., mTOR, JAK-STAT, MET, RET, or EGFR) in 16/20 
samples (41).
Unique genetically driven human PDAC have been reported 
to respond to targeted mTOR inhibition suggesting that preclini-
cal data are applicable in the treatment of human PDAC. During 
phase I treatment with MK-2206, a pan-AKT inhibitor, a dra-
matic 23% shrinkage in tumor was found in a patient with a loss 
of PTEN KRAS-dependent PDAC, which was thought to have 
occurred via PI3K–AKT–mTOR inhibition (43). Similarly, use 
of everolimus in a patient with Peutz–Jeghers syndrome-induced 
advanced pancreatic cancer with presumed mTOR hyperactiva-
tion through loss of STK11/LKB1 leads to 9 months progression-
free survival (44).
CLiniCAL TRiALS
Clinical Trials Utilizing mTOR inhibitors
Rapalogs monotherapy have not been shown to be effective 
in three phase II clinical trials of gemcitabine-refractory 
metastatic PDAC. Although treatment was well tolerated in a 
multi-institutional, single-arm, phase II study of everolimus in 
patients with gemcitabine-refractory metastatic PDAC, there 
were no significant improvements in progression-free survival 
or overall survival (45). The most common grade 3 and 4 
treatment-related toxicities were thrombocytopenia and hyper-
glycemia, respectively, leading to delay in treatment; however, 
no patients were removed from treatment due to drug-related 
adverse effects. In an open label, single-arm phase II study 
in gemcitabine-refractory metastatic PDAC patients treated 
with either temsirolimus or everolimus/erlotinib, there was 
similarly no demonstrated improvement in clinical responses 
(46). Significant systemic toxicity leads to premature cessation 
of patient enrollment for patients treated with temsirolimus. 
Treatment with everolimus/erlotinib therapy was tolerated; 
however, enrollment was also prematurely ended due to pro-
gression of disease on therapy.
Although not a direct mTOR inhibitor, MK-2206, an allos-
teric AKT inhibitor, with selumetinib, a MEK1/MEK2 inhibitor, 
were included in phase II trial concerning metastatic PDAC 
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failing gemcitabine-based therapy. Patients were randomized 
to treatment groups MK-2206 135 mg weekly plus selumetinib 
100 mg daily (MS) or mFOLFOX6 (without 5-FU bolus) every 
2 weeks. The most common toxicities, including rash, mucositis, 
dehydration, and fatigue, were observed in 34 patients in the MS 
arm compared to hematologic toxicities, fatigue, nausea, and 
vomiting observed in 19 patients in the mFOLFOX arm. MS did 
not improve overall survival, and shorter survival was observed 
compared to mFOLFOX [median OS 4.0 vs. 7.5 months, hazard 
ratio (HR) 1.46, 95% CI 0.90–2.38] (47).
Recently, combination therapy with capecitabine (5-FU 
prodrug) and everolimus in a phase II trial of the first-line and 
second-line treatment of PDAC demonstrated modest benefit 
to combined therapy over monotherapy (48). Median overall 
survival with combination therapy was 12.4 months in first-line 
patients and 5.9  months in second-line patients compared to 
historical rates of overall survival with capecitabine monotherapy 
of 5.9 months in first-line patients and 5.0 months in second-line 
patients suggesting that addition of everolimus to capecitabine 
might enhance efficacy of capecitabine monotherapy, especially 
in first-line patients.
Limitations of the aforementioned trials include the lack of 
characterization of the molecular pathology underlying PDAC 
tumorigenesis, which preclinical data suggest would predict 
treatment response. The modest improvement noted in the 
combined therapy everolimus/capecitabine phase II study sup-
ports the notion that coordinated inhibition of downstream 
KRAS signaling may improve antitumor efficacy of therapy 
(NCT01337765, NCT01324258, and NCT01562899).
COnCLUSiOn
Although initial trials targeting mTOR inhibition have generally 
failed to demonstrate treatment efficacy, specifically targeting 
therapy to the diverse mutations underlying KRAS-dependent 
PDAC in specific subpopulations offer potential for coordinated 
inhibition of synergistic trophic mechanisms and the resistance-
related feedback mechanisms underlying tumorigenesis. 
Targeting these mutations offers the advantage of improved tumor 
treatment with the potential for less systemic toxicity. Inhibition 
of patient-specific mTOR activity has strong preclinical data. 
Although many initial clinical trials with mTOR inhibition have 
been negative, the coordinated inhibition of multiple steps along 
the mTOR pathway may offer a viable alternative form of treat-
ment for genetically defined PDAC in the future. Results from 
further late-phase studies involving combined mTOR pathway 
inhibition are eagerly awaited.
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